B
BVF Partners L.P.
+ を保有NCEL
+8.72%
3か月リターン
$2.724
-0.156 (-5.73%)終値時点
Loading chart…
- 高値
- 2.800
- 始値
- 2.800
- 出来高加重平均価格
- 2.72
- 出来高
- 11.24K
- 時価総額
- —
- 安値
- 2.645
- 売買代金
- 30.61K
- EV/EBITDA（TTM）
- 0.00
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
AI分析 of NewcelX AG (NCEL)
買いNewcelX AG (NCEL) appears to be a good buy right now due to its recent 5-day price increase of 6.84% and a favorable RSI of 52.57, suggesting a neutral to positive momentum. The company has announced a private placement at a 30% premium, which indicates strong market confidence and a commitment to advancing its lead program for Type 1 Diabetes. However, the main risk is its current ratio of 0.76, indicating potential liquidity issues.
バリュエーション指標
NewcelX AG（NCEL）の現在の予想PERは0.00で、5年平均は0.00です。
NCEL を保有するクジラ
イベントタイムライン
ニュース
8.507-31NewsfilterNewcelX Secures Private Placement to Advance Diabetes Therapy
- 5.007-08Newsfilter
NewcelX Appoints Diabetes Research Authority Dr. Camillo Ricordi to Advisory Board
- 8.507-08Newsfilter
Avaí Bio Completes GMP Master Cell Bank for Anti-Aging Therapy
- 8.507-01Newsfilter
NewcelX Completes Successful FDA Meeting, Advancing Diabetes Treatment
- 3.506-15Newsfilter
NewcelX Publishes AstroRx® Study Results
NCEL のよくある質問 — Alphio AI が回答
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ. It operates in the Healthcare sector.
NewcelX AG (NCEL) appears to be a good buy right now due to its recent 5-day price increase of 6.84% and a favorable RSI of 52.57, suggesting a neutral to positive momentum. The company has announced a private placement at a 30% premium, which indicates strong market confidence and a commitment to advancing its lead program for Type 1 Diabetes. However, the main risk is its current ratio of 0.76, indicating potential liquidity issues.
コミュニティ
もっと見る ↗投稿はまだありません
登録またはログインして議論に参加関連記事
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。